Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 142-150

  Mutsaers, H A M ^a   Wilmer, M J G ^a   Reijnders, D ^a   Jansen, J ^a   van den Broek, P H H ^a   Forkink, M ^a   Schepers, E ^b   Glorieux, G ^b   Vanholder, R ^b   van den Heuvel, L P ^a,c   Hoenderop, J G ^a   Masereeuw, R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chronic kidney disease; Drug metabolism; Mitochondria; UDP glucuronosyltransferases; Uremic toxins

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; INDICAN; INDOLEACETIC ACID; KYNURENIC ACID; PHENYLACETIC ACID; SUCCINATE DEHYDROGENASE; UMBELLIFERONE; UREMIC TOXIN;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HEK293; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ELECTRON TRANSPORT; ENZYME ACTIVITY; FLOW CYTOMETRY; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INHIBITION KINETICS; KIDNEY METABOLISM; KIDNEY TUBULE CELL; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE; CRESOLS; DRUG TOXICITY; ELECTRON TRANSPORT; GLUCURONOSYLTRANSFERASE; HUMANS; KIDNEY; MITOCHONDRIA; PHARMACEUTICAL PREPARATIONS; SUCCINATE DEHYDROGENASE; UMBELLIFERONES; UREMIA;

EID: 84868552956     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.09.006     Document Type: Article

References (63)

1. Dreisbach A.W., Lertora J.J. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metabol. Toxicol. 2008, 4:1065-1074.
2. Sun H., Frassetto L., Benet L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther. 2006, 109:1-11.
3. Verbeeck R.K., Musuamba F.T. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur. J. Clin. Pharmacol. 2009, 65:757-773.
4. Yavuz A., Tetta C., Ersoy F.F., D'intini V., Ratanarat R., De C.M., Bonello M., Bordoni V., Salvatori G., Andrikos E., Yakupoglu G., Levin N.W., Ronco C. Uremic toxins: a new focus on an old subject. Semin. Dial. 2005, 18:203-211.
5. Jourde-Chiche N., Dou L., Cerini C., Gnat-George F., Vanholder R., Brunet P. Protein-bound toxins-update 2009. Semin. Dial. 2009, 22:334-339.
6. Vanholder R., Van L.S., Glorieux G. What is new in uremic toxicity?. Pediatr. Nephrol. 2008, 23:1211-1221.
7. Meyer T.W. The removal of protein-bound solutes by dialysis. J. Ren. Nutr. 2012, 22:203-206.
8. Lohr J.W., Willsky G.R., Acara M.A. Renal drug metabolism. Pharmacol. Rev. 1998, 50:107-141.
9. Simard E., Naud J., Michaud J., Leblond F.A., Bonnardeaux A., Guillemette C., Sim E., Pichette V. Downregulation of hepatic acetylation of drugs in chronic renal failure. J. Am. Soc. Nephrol. 2008, 19:1352-1359.
10. Bateman D.N., Gokal R., Dodd T.R., Blain P.G. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur. J. Clin. Pharmacol. 1981, 19:437-441.
11. Verbeeck R.K. Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review. Drug Metab. Dispos. 1982, 10:87-89.
12. Howie M.B., Bourke E. Metabolism of p-aminobenzoic acid in the perfused livers of chronically uraemic rats. Clin. Sci. (Lond.) 1979, 56:9-14.
13. Osborne R., Joel S., Grebenik K., Trew D., Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin. Pharmacol. Ther. 1993, 54:158-167.
14. Dreisbach A.W. The influence of chronic renal failure on drug metabolism and transport. Clin. Pharmacol. Ther. 2009, 86:553-556.
15. Kim Y.G., Shin J.G., Shin S.G., Jang I.J., Kim S., Lee J.S., Han J.S., Cha Y.N. Decreased acetylation of isoniazid in chronic renal failure. Clin. Pharmacol. Ther. 1993, 54:612-620.
16. Uchaipichat V., Mackenzie P.I., Guo X.H., Gardner-Stephen D., Galetin A., Houston J.B., Miners J.O. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos. 2004, 32:413-423.
17. Zhou J., Tracy T.S., Remmel R.P. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab. Dispos. 2011, 39:322-329.
18. Meert N., Schepers E., Glorieux G., Van L.M., Goeman J.L., Waterloos M.A., Dhondt A., Van der E.J., Vanholder R. Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrol. Dial. Transplant. 2012, 27:2388-2396.
19. Niwa T., Miyazaki T., Tsukushi S., Maeda K., Tsubakihara Y., Owada A., Shiigai T. Accumulation of indoxyl-beta-d-glucuronide in uremic serum: suppression of its production by oral sorbent and efficient removal by hemodialysis. Nephron 1996, 74:72-78.
20. Agatsuma S., Sekino H., Watanabe H. Indoxyl-beta-d-glucuronide and 3-indoxyl sulfate in plasma of hemodialysis patients. Clin. Nephrol. 1996, 45:250-256.
21. Ohno S., Nakajin S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 2009, 37:32-40.
22. Bock K.W. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem. Pharmacol. 2010, 80:771-777.
23. Gibson G.G., Skett P. Pathways of drug metabolism. Introduction to Drug Metabolism 1995, Chapman & Hall, London. Second ed.
24. Braun L., Kardon T., Puskas F., Csala M., Banhegyi G., Mandl J. Regulation of glucuronidation by glutathione redox state through the alteration of UDP-glucose supply originating from glycogen metabolism. Arch. Biochem. Biophys. 1997, 348:169-173.
25. Kerdpin O., Knights K.M., Elliot D.J., Miners J.O. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem. Pharmacol. 2008, 76:249-257.
26. Yu C., Ritter J.K., Krieg R.J., Rege B., Karnes T.H., Sarkar M.A. Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats. Drug Metab. Dispos. 2006, 34:621-627.
27. Cohen G., Glorieux G., Thornalley P., Schepers E., Meert N., Jankowski J., Jankowski V., Argiles A., Anderstam B., Brunet P., Cerini C., Dou L., Deppisch R., Marescau B., Massy Z., Perna A., Raupachova J., Rodriguez M., Stegmayr B., Vanholder R., Horl W.H. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. Nephrol. Dial. Transplant. 2007, 22:3381-3390.
28. Feigenbaum J., Neuberg C.A. Simplified method for the preparation of aromatic sulfuric acid esters. J. Am. Chem. Soc. 1941, 63:3529-3530.
29. Van der Eycken E., Terryn N., Goeman J.L., Carlens G., Nerinckx W., Claeyssens M., Van der Eycken J., Van Montagu M., Brito-Arias M., Engler G. Sudan-β-d-glucuronides and their use for the histochemical localization of β-glucuronidase activity in transgenic plants. Plant Cell Rep. 2000, 19:966-970.
30. Wilmer M.J., Saleem M.A., Masereeuw R., Ni L., Van D., Russel V.F.G., Mathieson P.W., Monnens L.A., van den Heuvel L.P., Levtchenko E.N. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res. 2009, 339:449-457.
31. Wittgen H.G.M., van den Heuvel J.J.M.W., van den Broek P.H.H., Siissalo S., Groothuis G.M.M., de Graaf I.A.M., Koenderink J.B., Russel F.G.M. Transport of the coumarin metabolite 7-hydroxycoumarin glucuronide is mediated via multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 2012, 40:1076-1079.
32. Hutter E., Renner K., Pfister G., Stockl P., Jansen-Durr P., Gnaiger E. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem. J. 2004, 380:919-928.
33. Mutsaers H.A., van den Heuvel L.P., Ringens L.H., Dankers A.C., Russel F.G., Wetzels J.F., Hoenderop J.G., Masereeuw R. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One 2011, 6:e18438.
34. Lash L.H., Putt D.A., Cai H. Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 2008, 244:56-65.
35. Schaaf G.J., de Groene E.M., Maas R.F., Commandeur J.N., Fink-Gremmels J. Characterization of biotransformation enzyme activities in primary rat proximal tubular cells. Chem. Biol. Interact. 2001, 134:167-190.
36. R. Moghadasali, H.A. Mutsaers, M. Azarnia, N. Aghdami, H. Baharvand, R. Torensma, M.J. Wilmer, R. Masereeuw, Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity, Exp. Toxicol. Pathol. (in press), http://dx.doi.org/10.1016/j.etp.2012.06.002.
37. Vanholder R., Bammens B., de L.H., Glorieux G., Meijers B., Schepers E., Massy Z., Evenepoel P. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol. Dial. Transplant. 2011, 26:1464-1467.
38. Wang P., Henning S.M., Heber D. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010, 5:e10202.
39. Lancaster C.R. Succinate:quinone oxidoreductases: an overview. Biochim. Biophys. Acta 2002, 1553:1-6.
40. + metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Redox Rep. 2012, 17:28-46.
41. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
42. Rhee E.P., Souza A., Farrell L., Pollak M.R., Lewis G.D., Steele D.J., Thadhani R., Clish C.B., Greka A., Gerszten R.E. Metabolite profiling identifies markers of uremia. J. Am. Soc. Nephrol. 2010, 21:1041-1051.
43. Fukuwatari T., Morikawa Y., Hayakawa F., Sugimoto E., Shibata K. Influence of adenine-induced renal failure on tryptophan-niacin metabolism in rats. Biosci. Biotechnol. Biochem. 2001, 65:2154-2161.
44. Owada S., Maeba T., Sugano Y., Hirayama A., Ueda A., Nagase S., Goto S., Nishijima F., Bannai K., Yamato H. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation. Nephron Exp. Nephrol. 2010, 115:e101-e111.
45. Dzurik R., Spustova V., Krivosikova Z., Gazdikova K. Hippurate participates in the correction of metabolic acidosis. Kidney Int. Suppl. 2001, 78:S278-S281.
46. Kitagawa A. Effects of cresols (o-, m-, and p-isomers) on the bioenergetic system in isolated rat liver mitochondria. Drug Chem. Toxicol. 2001, 24:39-47.
47. Riegel W., Ulrich C., Sauernheimer S., Deppisch R.M., Kohler H. Hepatotoxic substance(s) removed by high-flux membranes enhances the positive acute phase response. Kidney Int. Suppl. 2001, 78:S308-S314.
48. Vanholder R., De S.R., Glorieux G., Argiles A., Baurmeister U., Brunet P., Clark W., Cohen G., De Deyn P.P., Deppisch R., Scamps-Latscha B., Henle T., Jorres A., Lemke H.D., Massy Z.A., Passlick-Deetjen J., Rodriguez M., Stegmayr B., Stenvinkel P., Tetta C., Wanner C., Zidek W. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003, 63:1934-1943.
49. Jankowski J., van der G.M., Jankowski V., Schmidt S., Hemeier M., Mahn B., Giebing G., Tolle M., Luftmann H., Schluter H., Zidek W., Tepel M. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J. Clin. Invest. 2003, 112:256-264.
50. Duranton F., Cohen G., De S.R., Rodriguez M., Jankowski J., Vanholder R., Argiles A. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 2012, 23:1258-1270.
51. Deguchi T., Ohtsuki S., Otagiri M., Takanaga H., Asaba H., Mori S., Terasaki T. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int. 2002, 61:1760-1768.
52. Deguchi T., Kusuhara H., Takadate A., Endou H., Otagiri M., Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004, 65:162-174.
53. Toyohara T., Suzuki T., Morimoto R., Akiyama Y., Souma T., Shiwaku H.O., Takeuchi Y., Mishima E., Abe M., Tanemoto M., Masuda S., Kawano H., Maemura K., Nakayama M., Sato H., Mikkaichi T., Yamaguchi H., Fukui S., Fukumoto Y., Shimokawa H., Inui K., Terasaki T., Goto J., Ito S., Hishinuma T., Rubera I., Tauc M., Fujii-Kuriyama Y., Yabuuchi H., Moriyama Y., Soga T., Abe T. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J. Am. Soc. Nephrol. 2009, 20:2546-2555.
54. Mutsaers H.A., Wilmer M.J., van den Heuvel L.P., Hoenderop J.G., Masereeuw R. Basolateral transport of the uraemic toxin p-cresyl sulfate: role for organic anion transporters?. Nephrol. Dial. Transplant. 2011, 26:4149.
55. Saito A., Nagai R., Tanuma A., Hama H., Cho K., Takeda T., Yoshida Y., Toda T., Shimizu F., Horiuchi S., Gejyo F. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. J. Am. Soc. Nephrol. 2003, 14:1123-1131.
56. Masereeuw R., Moons M.M., Russel F.G. Renal excretion and accumulation kinetics of 2-methylbenzoylglycine in the isolated perfused rat kidney. J. Pharm. Pharmacol. 1996, 48:560-565.
57. Masereeuw R., Moons M.M., Russel F.G. Disposition of 4-methylbenzoylglycine in rat isolated perfused kidney and effects of hippurates on renal mitochondrial metabolism. J. Pharm. Pharmacol. 1998, 50:1397-1404.
58. Leblond F.A., Giroux L., Villeneuve J.P., Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab. Dispos. 2000, 28:1317-1320.
59. Leblond F., Guevin C., Demers C., Pellerin I., Gascon-Barre M., Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol. 2001, 12:326-332.
60. Naud J., Michaud J., Beauchemin S., Hebert M.J., Roger M., Lefrancois S., Leblond F.A., Pichette V. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab. Dispos. 2011, 39:1363-1369.
61. Sun H., Huang Y., Frassetto L., Benet L.Z. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 2004, 32:1239-1246.
62. Huang Z.H., Murakami T., Okochi A., Yumoto R., Nagai J., Takano M. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur. J. Pharmacol. 2000, 406:453-460.
63. Knights K.M., Miners J.O. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab. Rev. 2010, 42:63-73.